News Search Results

Displaying Results 126-150 of 489 "series C"

Jan 16, 2026, 16:01 ET MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

common stock (or common stock equivalents), 4,508,361 Series C Warrants and 4,508,361 Series D Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C Warrants and Series D Warrants. The Series C Warrants are immediately exercisable, have an exercise

More news about: MetaVia Inc.


Jan 16, 2026, 06:00 ET Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock

of a newly designated Series F Exchangeable Preferred Stock (the "Series F Preferred Stock") to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of

More news about: Hyperscale Data Inc.


Jan 15, 2026, 16:15 ET Invesco Mortgage Capital Inc. Announces Monthly Common Dividend and Provides Update on Book Value and Leverage

stock dividend that was declared on January 15, 2026 and is calculated as total stockholders' equity less the liquidation preference of the Company's Series C Preferred Stock ($171.0 million as of January 12, 2026), divided by total common shares outstanding of 76.3 million.

More news about: Invesco Mortgage Capital Inc.


Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in NowRx, Inc. of Class Action Lawsuit and Upcoming Deadlines

and this $3.55 per share price was significantly less than the $10.50 per share offering price in the Company's Series C stock offering in 2022; and (5) as a result, investors in the Series C stock offering would likely lose their investment.Pomerantz LLP, with offices in New York, Chicago, Los

More news about: Pomerantz LLP


Jan 15, 2026, 09:32 ET MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

common stock (or common stock equivalents), 3,920,316 Series C Warrants and 3,920,316 Series D Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C Warrants and Series D Warrants. The Series C Warrants are immediately exercisable, have an exercise

More news about: MetaVia, Inc.


Jan 15, 2026, 09:05 ET Parloa Valued at $3 Billion with $350M Series D to Lead Agentic AI for Customer Experience

Closing just seven months after its Series C, this round brings Parloa's total raised capital to more than $560 million in less than four years. The company will use the funds to continue its

More news about: Parloa


Jan 15, 2026, 08:30 ET Mytra Raises $120M Series C to Scale Operating System for Supply Chain

remarkable velocity - executing with intensity, deploying to customers, and implementing feedback pragmatically. We're thrilled to lead their Series C."The Series C funding will accelerate deployment scaling to meet customer demand and fuel strategic talent acquisition. Mytra has over 20 open roles and

More news about: Mytra


Jan 14, 2026, 12:20 ET osapiens secures US$ 100 million Financing and Becomes a Unicorn with investment from BlackRock- and Temasek-founded Decarbonization Partners

announced that it had entered into an agreement for Decarbonization Partners, a joint venture between BlackRock and Temasek, to lead a US$ 100 million Series C fundraising round, subject to regulatory approvals. Decarbonization Partners

More news about: osapiens


Jan 14, 2026, 12:18 ET osapiens secures US$ 100 million Financing and Becomes a Unicorn with investment from BlackRock- and Temasek-founded Decarbonization Partners

announced that it had entered into an agreement for Decarbonization Partners, a joint venture between BlackRock and Temasek, to lead a US$ 100 million Series C fundraising round, subject to regulatory approvals. Decarbonization Partners

More news about: osapiens


Jan 14, 2026, 11:12 ET osapiens haalt 100 miljoen USD aan financiering binnen en wordt een eenhoorn dankzij investering van Decarbonization Partners, opgericht door BlackRock en Temasek

gesloten voor Decarbonization Partners, een samenwerkingsverband tussen BlackRock en Temasek, om onder voorbehoud van wettelijke goedkeuringen een Series C-fundraisingronde van 100 miljoen USD te leiden.. Decarbonization Partners zal

More news about: osapiens


Jan 14, 2026, 11:05 ET Quadric, Inference Engine for On-Device AI Chips, Raises $30M Series C as Design Wins Accelerate Across Edge LLMs, Automotive, and Enterprise

2026 /PRNewswire/ -- Quadric®, the inference engine that powers on-device AI chips, today announced an oversubscribed $30 million Series C funding round, bringing total capital raised to $72 million.

More news about: Quadric, Inc.


Jan 14, 2026, 08:00 ET Global Açai Brand OAKBERRY Taps Qu's Unified Commerce Platform to Anchor U.S. Expansion

measurable revenue lift."OAKBERRY's deployment of Qu comes as part of a broader expansion strategy. In 2024, OAKBERRY raised $67 million in Series C Funding, noting a focus on growth in the U.S. The brand currently operates more than 50 locations and has a development pipeline of more than 250

More news about: Qu


Jan 14, 2026, 06:08 ET Xoxoday Raises Series-C to Accelerate Global Expansion

Jan. 14, 2026 /PRNewswire/ -- Xoxoday, a global rewards, incentives, and Loyalty technology company, has raised a Series C round backed by its existing investors - Apis Partners & 57 Stars, marking a key milestone as the company accelerates its next phase of global

More news about: Xoxoday


Jan 14, 2026, 06:00 ET Hyperscale Data Announces 43 Consecutive Months of Cash Dividend Payments Timely Paid on its Series D Cumulative Redeemable Perpetual Preferred Stock

of a newly designated Series F Exchangeable Preferred Stock (the "Series F Preferred Stock") to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of

More news about: Hyperscale Data Inc.


Jan 13, 2026, 17:31 ET Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight

Priority Medicines (PRIME) designation for sHLH.In October 2025, Electra Therapeutics announced an oversubscribed USD 183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala

More news about: DelveInsight Business Research, LLP


Jan 13, 2026, 08:52 ET Clinical Intelligence Gains Momentum Across Health Plans as Cohere Health Sees Record 2025 Growth

focused on what matters most: getting every patient to the right care, at the right time."Cohere Health's growth was fueled by its $90 million Series C funding announced in May. This investment supported the expansion of the company's clinical intelligence platform across applications, copilots, agents,

More news about: Cohere Health


Jan 13, 2026, 06:49 ET Flagging notification due to share repurchase

shares . Following the transaction, Truecallers's total holding of treasury shares amounts to 12,739,926 series B shares and 5,013,786 series C shares, a total of 17,753,712 shares corresponding to 5.02 percent of the total number of shares in the company, thereby exceeding the five percent

More news about: Truecaller AB


Jan 13, 2026, 06:00 ET Hyperscale Data Bitcoin Treasury at 539.5929 Bitcoin

of a newly designated Series F Exchangeable Preferred Stock (the "Series F Preferred Stock") to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of

More news about: Hyperscale Data Inc.


Jan 12, 2026, 20:44 ET Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies

Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing. The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global

More news about: OriCell Therapeutics Co., Ltd.


Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion

candidates that appeared highly potent against multidrug-resistant "superbugs."Basecamp Research also adds NVentures as an investor ahead of Series C round following deep technical collaboration on EDEN models.LONDON and CAMBRIDGE,

More news about: Basecamp Research


Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion

candidates that appeared highly potent against multidrug-resistant "superbugs."Basecamp Research also adds NVentures as an investor ahead of Series C round following deep technical collaboration on EDEN models.LONDON and CAMBRIDGE,

More news about: Basecamp Research


Jan 12, 2026, 10:00 ET Basecamp Research bringt weltweit erste KI-Modelle für die programmierbare Gen-Insertion auf den Markt

Kandidaten, die sich als hochwirksam gegen multiresistente „Superbugs" erwiesen.Basecamp Research gewinnt außerdem NVentures als Investor vor der Series C-Finanzierungsrunde nach intensiver technischer Zusammenarbeit bei EDEN-Modellen.LONDON

More news about: Basecamp Research


Jan 12, 2026, 10:00 ET 베이스캠프 리서치, 세계 최초 프로그램 가능한 유전자 삽입 AI 모델 출시

재프로그래밍하는 새로운 방식을 제시한다. 엔비디아와의 협력을 통해 학습된 이 모델들은 암 및 유전 질환에 대한 차세대 치료제 개발을 주도하고 있다. 이와 함께 베이스캠프 리서치는 수년간의 긴밀한 기술 협력 끝에 엔비디아의 벤처캐피털 부문인 엔벤처스로부터 프리 시리즈 C(pre-Series C) 투자를 유치했으며, 이를 통해 연구 개발 노력을 가속할 방침이다. 존 핀(John Finn) 베이스캠프 리서치 최고과학책임자(CSO)는 "우리는 암과 유전 질환 환자들이 선택할

More news about: Basecamp Research


Jan 12, 2026, 01:48 ET EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics

system uses a special bioabsorbable patch to seal large access sites in arteries or veins from the inside EQT supported Vivasure from its Series C investment in 2016 through clinical development and toward market approvalSTOCKHOLM, Jan.

More news about: EQT


Jan 09, 2026, 22:30 ET Rain haalt $ 250 miljoen op in Series C-financieringsronde om de betalingsinfrastructuur die door stablecoin mogelijk wordt gemaakt op te schalen voor wereldwijde ondernemingen

Rain, de infrastructuur op bedrijfsniveau voor betalingen met stablecoin, heeft vandaag een Series C-financieringsronde van $ 250 miljoen aangekondigd onder leiding van ICONIQ, met deelname van Sapphire Ventures, Dragonfly, Bessemer Venture Partners,

More news about: Rain


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.